Pharmacyclics — Technical Presentation (December 2013)
20 slides from Pharmacyclics's technical presentation, Dec 11, 2013
Slide 1: Ibrutinib Monotherapy Long-Term Safety and Durability of Response in CLL/SLL
The Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Monotherapy Demonstrates Long-Term Safety and Durability of Response in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients in an Open-Label Extension Study Susan O’Brien, MD}, Richard Furman, MD?, Nathan Fowler, MD3, St
Slide 2: Introduction
Introduction Bruton’s tyrosine kinase (BTK) plays a critical role in chronic lymphocytic leukemia (CLL) cell survival by modulating B-cell receptor signaling! ™ |brutinib (PCI-32765), a first-in-class oral inhibitor of BTK, inhibits proliferation, migration, and adhesion in CLL cells? ™ A total of 1
Slide 3: BTK is a Critical Kinase for Lymphoma Cell Survival, Proliferation, and Migration
BTK is a Critical Kinase for Lymphoma Cell Survival, Proliferation, and Migration Chemokine-controlled cell migration Cell Survival ‘OBrien et al, ASH 2013, 3
Slide 4: Objective
™ Evaluate the safety and efficacy of ibrutinib monotherapy in TNand R/R patients with CLL/SLL ‘OBrien et al, ASH 2013, 4
Slide 5: Endpoints: Safety, ORR, and DOR
™ Safety, ORR, and DOR ‘OBrien et al ASH 2013 5
Slide 6: Methods
= The methods used in the parent studies (PCYC-04753 and PCYC-1102-CA) of the current open-label extension PCYC-1103-CA study have been previously published? = Demographics and baseline characteristics were summarized according to parent study, comprising either TN patients or R/R CLL/SLL patients w
Slide 7: Patient and Disease Characteristics
Patient and Disease Characteristics _— TN 2 65 years R/R Total Characteristic, n (%) (n=31) (n= 117) (N=148) Median age, years (range) 71 (65-84) 65 (37-82) 68 (37-84) Age 2 65 years 31 (100) 60 (51) 91 (61) 23 prior therapies 0 83 (71) 83 (56) Raistage Ill or lV 17 (54) 62 (53) 79 (53) O'Brien et a
Slide 8: Patient Disposition and Time on Treatment
Patient Disposition and Time on Treatment a tic, ni (9%) | TN 2 65 years (n = 31) R/R(n Median time on study treatment, months (range) 26.7 (0334.0) 20.5(0.3-42.0) —21.5(0.3-42.0), Median time on study®, months (range) 27.8 (1.4340) 22.7(0.7°-41.9) 25.9 (0.7"-41.9) Treatment duration, years <1 5(16)
Slide 9: Safety: Adverse Events Grade by Time to Event Onset
Safety: Adverse Events Grade 2 3 by Time to Event Onset | AE Onset <1 yearFromFirst | AE Onset >4 year From Sea) Dose Date [N= 148) First Dose Date {n = 109 Patients with an event 88 56 Pheumonia 15(10.1) 12(11.0) 25(16.9) Treatment duration, years <a 5 (16) 3429), 39(26), >1to2 5 (16) 42(36) 47(32)
Slide 10: Safety: Adverse Events Grade by Time to Event Onset (Continued)
Safety: Adverse Events Grade 2 3 by Time to Event Onset (Continued) Hypokalemia 24) 2U.8) Sepsis 2(1.a) 2(1.8) Asthenia 3(2.0) o Backpain 2(1.8) 1(09) Dyspnea 2(1.4) 1 (0.9) Headache 2(1.d) 110.9) Hyperbilirubinemia 1(07) 2.8) Hyperelycemia 2(1.8) 1(0.9) Hyperkalemia 3(20) ° Hypoglycemia 2(1.a) 110.
Slide 11: Safety: Adverse Events Grade by Time to Event Onset (Continued)
Safety: Adverse Events Grade 2 3 by Time to Event Onset (Continued) ™ The percentage of patients with a serious AE grade 2 3 declined from 43% within the first year of study treatment to 32% after the first year of treatment ™ Grade 3 AEs and serious AEs related to study drug declined from 24% and 8
Slide 12: Safety: Adverse Events With Incidence ≥ 2%
Safety: Adverse Events 2 3 With Incidence = 2% Patients with an event Pneumonia 2(6.5) 23(19.7) Hypertension 6 (19.4) 14 (129) Neutropenia 1(3.2) 1613.7) ‘Thrombocytopenia 13.2) 10(85) Diarrhea 4129) 403.4) Fatigue 113.2) 6(54) Leukocytosis 0 6 (5.1) ‘Arial fibrillation 2165) 3(26) Cellulitis ° 5(43
Slide 13: Safety: Adverse Events With Incidence ≥ 2% (Continued)
Safety: Adverse Events 2 3 With Incidence 2 2% (Continued) Adverse Event, n(%) Hypokalemia Sepsis Asthenia ° Backpain 1(3.2) Dyspnea 0 Headache 132) Hyperbilicubinemia ° Hyperelycemia 1(3.2) Hyperkalemia 1132) Hypoglycemia o Hyponatremia 319.7) Hypophosphatemia ° Decreased lymphocyte count 113.2) In
Slide 14: Safety: Adverse Events Grade ≥ 3 With Incidence ≥ 2% (Continued)
Safety: Adverse Events > 3 With Incidence > 2% (Continued) ™ Adverse events grade 2 3 included pneumonia (16.9%), hypertension (13.5%), neutropenia (11.5%), thrombocytopenia (7.4%), and diarrhea (5.4%), regardless of relationship to study drug ™ Serious AEs grade 23 were reported in 29% of TN and 62
Slide 15: Treatment-Emergent Related Adverse Events Grade ≥3 With Incidence ≥ 2%
Treatment-Emergent Related Adverse Events Grade 2 3 With Incidence 2 2% (Monotherapy Safety Population) Neutropenia Grades Diarrhea Grade 4 Fatigue ‘Thrombocytopenia Asthenia Hypertension Leukocytosis Pneumonia 0% 5% 10% 15% 20% 25% 30% AES ‘OBrien et al, ASH 2013, 15
Slide 16: Efficacy: Best Overall Response
Efficacy: Best Overall Res TN 265 years R/R Total Response Rate, n (%) (n= 31) (n= 117) (N= 148) ORR? 25 (80.6) 98 (83.8) 123 (83.1) ORR + PR-L 27 (87.1) 104 (88.9) 131 (88.5) *ORR defined as complete response, complete response with incomplete bone marrow recovery, nodular Partial response, or part
Slide 17: Duration of Response in R/R or TN CLL Patients
Duration of Response In R/R or TN CLL Patients "= Median DOR was not reached for either TN or R/R responders achieving PR or better, after a median follow-up of 28.1 and 23.9 months, respectively = At30 months, 95.8% and 69.7% of R/R responders were alive without disease progression 10 — aR —w 8 = i
Slide 18: Conclusions
Conclusions ™ |brutinib demonstrated safety, tolerability, and durability of response at 2 1 year on therapy in patients with TN and R/R CLL/SLL ™ The number of patients experiencing serious AEs or AEs grade > 3 after 1 year of treatment with ibrutinib decreased, resulting in low rates of treatment-
Slide 19: Acknowledgments
Acknowledgments ™ We thank the patients who participated in this study and their families, as well as the investigators and their clinical and clinical trial staff members. ™ This study was conducted by Pharmacyclics, Inc ™ IF, JCB, SO, JJ, KK, NF, SC, and JB have received research funding from Phar
Slide 20: References
References 1. Niiro and Clark. Nat Rev Immunol. 2002;2:945-956. 2. Honigberg et al. Proc Natl Acad Sci U S$ A. 2010;107:13075- 13080. Advani et al. J Clin Oncol. 2013;31:88-94. 4. Byrd et al. N Engl J Med. 2013;369:32-42. » ‘OBrien et al, ASH 2013, 20
Pharmacyclics — Technical Presentation (December 2013) on 6ix